ArticleOphthalmology science2021

Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema.

Arshad M Khanani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.